Prior therapy with an anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or anti-cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways); examples include nivolumab, MPDL, etc
Has received prior therapy with an anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or anti-CTLA- antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
No prior systemic treatment with an anti-PD-, anti-PD-L, anti-PD-L, anti-CTLA- antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways;
While prior therapy with nivolumab, pembrolizumab, or atezolizumab is allowed, any prior therapy with other anti-PD-, anti-PD-L, anti-PD-L, anti-CD, anti-CTLA- antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways) is not allowed
Prior treatment with immune checkpoint inhibitors (eg, anti-CTLA-, anti-PD-, anti-PD-L, and any other antibody or drug specifically targeting T-cell co-stimulation) or an IDO inhibitor (exception is tumor types in which a PD- pathway targeted agent is approved, e.g. melanoma, non-small cell lung cancer.)
Subjects who have received prior therapy with any T cell co-stimulation or checkpoint pathways such as anti-PD-, anti-PD-L, anti-PD-L, anti-CTLA-, anti-CD; or other medicines specifically targeting T cells are prohibited. Prior IL- is permitted.
Prior treatment with an anti-PD-, anti-PD-L, anti-PD-L, or anti-CTLA- antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Patients must not have received prior immuno-oncology regimens, including but not limited to inhibitors such as anti PD-, anti-PD-L, anti-PD-L, anti CD, or anti CTLA- (cytotoxic T lymphocyte-associated protein ) antibody, or any other antibody or drug specifically targeting T cell co stimulation or checkpoint pathways, indoleamine ,-dioxygenase pathway inhibitors, cancer vaccines, adoptive cell therapies, or other cytokine therapies.
Patients that have had prior treatment with an anti-PD-, anti-PD-L, anti-PD-L, anti-CTLA- antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways are eligible, unless they discontinued such therapy due to toxicity
Participants who have had prior treatment with an anti-PD-, anti-PD-L, anti-PD-L, anti-CTLA- antibody, or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways
Has received prior therapy with an anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or anti-cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Subject who has been treated with immunotherapy; this includes prior treatment with anti-PD-, anti-PD-L, anti-PD-L, anti-CTLA- antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Prior treatment with an anti-PD-, anti-PD-L, anti-PD-L, anti-CTLA- antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways
PHASE II EXCLUSION CRITERIA: Prior treatment with an anti-PD-, anti-PD-L, anti-PD-L, anti-CTLA- antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways
Has received prior therapy with an anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or IDO inhibitor or any other antibody or drug specifically targeting checkpoint pathways other than anti-CTLA- which is permitted in the adjuvant setting.
Prior treatment with any MEK inhibitor, an anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or anti-CTLA- antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.
Prior therapy with any of the following: PD-, PD-L, CTLA antibody, or any other drug targeting T cell checkpoint pathways.
Prior treatment with an anti-PD-, anti-PD-L, anti-PD-L, anti-CTLA- antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways
Prior therapy with an anti-PD-, anti-PD-L, anti-PDL-, or anti-CTLA- antibody (or any other antibody targeting T cell co-regulatory pathways)
Prior therapy with anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or anti-CTLA- antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways)
Prior receipt of survivin based vaccines or immune checkpoint inhibitors (e.g. anti-CTLA-, anti-PD-, anti-PD-L, or any other antibody or drug specifically targeting T cell co-stimulation) or an IDO inhibitor
Has received prior therapy with an anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or anti-cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Patients who have received previous therapy with an anti-CTLA, anti-CD, anti-PD-L or anti-PD- antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
EXCLUSION CRITERIA FOR STRATUM C: Patients who have received previous therapy with an anti-CTLA, anti-CD, anti-PD-L or anti-PD- antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Prior treatment with an anti-PD-, anti-PD-L, anti-PD-L, anti-cluster of differentiation (CD), or anti-cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Prior treatment with an anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or anti-cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Has received prior therapy with an anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or anti-cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways) for metastatic breast cancer-or- if patient has had prior immune-oncology therapies in the neoadjuvant or adjuvant setting within the past  months.
Prior therapy for melanoma with the following exceptions which are allowed: ) surgery for the melanoma lesion(s), ) adjuvant RT after neurosurgical resection for CNS lesions, and ) prior adjuvant IFN (see qualifier below); specifically, patients who received prior therapy with anti-PD-, anti-PD-L, anti-programmed death ligand- (PD-L), anti-clusters of differentiation (CD), or anti-CTLA- antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways) are not eligible\r\n* Prior treatment with adjuvant IFN is allowed if completed >=  months prior to treatment, and adjuvant ipilimumab if >=  months prior to treatment
Has received prior therapy with an anti-Cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Prior therapy with an anti-PD-, anti-PD-L, anti-PD-L, anti-CD or anti CTLA- antibody or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Prior treatment with an anti-PD-, anti-PD-L, anti-PD-L, anti-CTLA- antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
Prior treatment with an anti-PD-, anti-PD-L, anti-PD-L, anti-CTLA- antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Prior therapy with anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or anti-CTLA- antibody (or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways) is not permitted
MEDICATION-RELATED: Prior history of treatment with anti-PD-, anti-PD-L, anti-PD-L, anti-CD, anti-CTLA or any other antibodies targeting co-stimulation or checkpoint pathways.
No prior treatment with anti PD, anti PD L, anti CTLA  antibody or any other antibody or drugs targeting T cell costimulation or checkpoint pathways, or cetuximab or EGFR inhibitors in any treatment setting.
Any prior therapy with anti-PD-, anti-PD-L, anti-CTLA- antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
Any prior therapy with anti-PD-, anti-PD-L, anti-CTLA- antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
Prior therapy with anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or anti-CTLA- antibody (including ipilimumab or any other antibody or drug specifically targeting T cell costimulation or checkpoint pathways)
Has received prior therapy with an anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or anti-cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including pembrolizumab, ipilimumab, and any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Prior anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or anti-cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways) is allowed in part  (phase b) and is required for phase  cohort B of the study
Has received prior therapy with an anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or anti-cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways) for the immunotherapy-naive cohort only
Prior treatment with an anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or anti-CTLA- antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Any prior grade >=  immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade , including anti-PD-, anti-PD-L, anti-CD, anti-CTLA- antibody or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways, except for endocrinopathies and asymptomatic amylase/lipase
Prior treatment with an anti-PD-, anti-PD-L, anti-PD-L, anti-CTLA- antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Patients who have had prior treatment with an anti-PD, anti-PDL, anti-PDL, anti-CTLA antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways are not eligible
Prior treatment with an anti-PD-, anti-PD-L, anti-PD-L, anti-cytotoxic T-lymphocyte-associated protein  (anti-CTLA-) antibody, anti-CD, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
Prior treatment with an anti-CD, or OX antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways except anti-PD, anti-PDL/ antibodies or ipilimumab
Progression while on prior therapy with an anti-programmed cell death (PD)-, anti-PD-L, anti-PD-L, anti-tumor necrosis factor CD, or anti-cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent; anti-CD or anti-cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Prior treatment with an anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or anti-CTLA- antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways; prior treatment with HD IL- is allowed
Has received prior therapy with an anti-PD-, anti-PD-L, anti-PD-L, or anti cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
* Patients should be excluded if they have had prior treatment with an anti-PD-, anti-PD-L, anti-PD-L, anti-CTLA- antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
Prior treatment with an anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or anti-CTLA- antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Has received prior therapy with an anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or anti-cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Has received prior therapy with an anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or anti- Cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Prior therapy with antibody or drug specifically targeting T cell regulatory proteins, including but not limited to: prior immunotherapy with IL- or IFN-alpha, or an anti-PD- (including nivolumab), anti-PD-L, anti-PD-L, anti-CD, or anti-cytotoxic T-lymphocyte associated antigen- (CTLA-) antibody (including ipilimumab), or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Has received prior therapy with an anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or anti-cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).
Prior therapy with anti-PD-, anti-PD-L, anti-PD-L, anti-CD, anti-CTLA- antibody therapies, any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways
Prior therapy with an anti-PD-, anti-PD-L, anti-PD-L, or anti-CTLA- antibody (or any other antibody targeting T cell co-stimulation pathways)
Patients who received prior treatment with an anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or anti-cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways) are not eligible
Has received prior therapy with an anti-PD-, PD-L, anti-CD, or anti-Cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Prior treatment with any anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or anti-CTLA- antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Has received prior therapy with an anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or anti-cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Has received prior therapy with an PD-, anti-PD-L, anti-PD-L, anti-CD, or anti-cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Has received prior therapy with an anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or anti-cytotoxic T-lymphocyte associated antigen- antibody (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Prior immunotherapy with IL-, IFN-?, or anti PD , anti PD L, anti PD L, anti CD, or anti cytotoxic T lymphocyte associated antigen  (CTLA ) antibody (including ipilimumab), or any other antibody or drug specifically targeting T cell co stimulation or immune checkpoint pathways
Subject has received prior therapy with an anti-PD-, anti-PD-ligand  (L), anti-PD-L, anti-cluster of differentiation (CD), or anti-cytotoxic T-lymphocyte-associated antigen- (CTLA-) agents (including ipilimumab), interferon, high dose interleukin  (IL-) or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Has received prior therapy with PD-, anti-PD-L, anti-PD-L, anti-CD, or anti-cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways) within  months
Has received prior therapy with an anti-programmed cell death (PD)-, anti-PD-L, anti-PD-L, anti-cluster of differentiation (CD), or anti-cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Has received prior therapy with an anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or anti-cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Has received prior therapy with an anti-PD-, anti-programmed cell death  ligand  (PD-L), anti-PD-L, anti-cluster of differentiation  (CD), or anti-cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways); prior treatment with interferon alfa is allowed; patients with history of allergic or hypersensitivity reaction to interferon alfa are excluded
Prior therapy with an anti-PD-, anti-PD-L, anti-PD-L, anti-cluster of differentiation (CD), or anti-cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Prior therapy with an anti-PD-, anti-PD-L, anti-PDL-, or anti-CTLA- antibody (or any other antibody targeting T cell co-regulatory pathways)
Has had prior treatment with an anti-PD- or anti-PD-L antibody, anti-cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab) or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways;
Prior treatment with an anti-programmed death- (PD-), anti-PD-L, anti PD L, anti-CD, or anti-cytotoxic T lymphocyte antigen- (CTLA-) antibody, or any other antibody or drug specifically targeting T-cell co stimulation or checkpoint pathways.
Patients should be excluded if they have had prior treatment with a Pi kinase inhibitor, anti-PD-, anti-PD-L, anti-PD-L, anti-CTLA- antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
ORAL CAVITY SQUAMOUS CELL CARCINOMA COHORT: Prior treatment with an anti-PD-, anti-PD-L, anti-PD-L, anti-CTLA- antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
HPV-ASSOCIATED OROPHARYNX SQUAMOUS CELL CARCINOMA: Prior treatment with an anti-PD-, anti-PD-L, anti-PD-L, anti-CTLA- antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Prior PD- or PD-L inhibitor therapy, or prior therapy with anti-PD-L or anti-CTLA- inhibitor, or any other drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
Has received prior therapy with an anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or anti-Cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Any previous treatment with a hypomethylating agent, or with a PD or PD-L or anti-PD-L or anti-CTLA inhibitor, including durvalumab (or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways); any immunomodulatory agent that is not described above should be cleared by the principal investigator (PI)
Prior treatment with an anti-PD, anti-PDL, anti-PDL, anti-CD, or anti-CTLA antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Prior therapy with anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or anti-CTLA- antibody (including ipilimumab or any other antibody or drug specifically targeting T cell co-stimulation or checkpoint pathways)
Prior therapy with an anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or anti- cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways)
Any prior therapy with anti-PD-, anti-PD-L, anti-CTLA- antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
Has received prior therapy with an anti-PD-, anti-PD-L, anti-programmed death-ligand  (PD-L), anti-cluster of differentiation (CD), or anti-Cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Patients are excluded if they have had prior treatment with an anti-PD-, anti-PD-L, anti-PD-ligand  (L), anti-cytotoxic T-lymphocyte-associated protein  (CTLA-) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
Has received prior therapy with an anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or anti-cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Patients who have had prior therapy with nivolumab or with an anti-PD-, anti-PD-ligand (L), anti-PD-L, anti-cytotoxic T-lymphocyte-associated protein  (CTLA-) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune check point pathways
Study participants who had prior treatment with anti-PD-, anti-PD-L, anti-PD-L, anti-CTLA- antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
Prior treatment with interferon (if complete <  months prior to participation in study), anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or anti-CTLA- antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Patients must not have had prior treatment with an anti-programmed cell death (PD)-, anti-PD-L, anti-PD-L, anti-cytotoxic T-lymphocyte-associated protein (CTLA)- antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways
Prior treatment with an anti-Programmed Death (PD) -, anti-PD-L, anti-PD-L, anti-cluster of differentiation  (CD), or anti-cytotoxic T-lymphocyte-associated antigen (CTLA-) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways. This includes the utilization of these agents in the neo-adjuvant or adjuvant setting.
Prior treatment with an anti-Programmed Death Receptor (PD)-, anti-PD-L, anti-PD-L, anti-Cytotoxic T-Cell Lymphoma- Antigen (CTLA-) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
Has received prior therapy with an anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or anti-Cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways). Exception: Prior anti?CTLA- in the adjuvant setting for subjects with melanoma would be permitted.
Prior therapy with an antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways, including, but not limited to, anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or anti-cytotoxic T lymphocyte associated antigen  (anti-CTLA-) antibody.
Has received prior therapy with an anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or IDO inhibitor or any other antibody or drug specifically targeting checkpoint pathways other than anti-CTLA- which is permitted in the adjuvant setting
Prior systemic anti-cancer treatment for EOC, FTC, or PPC including prior immunotherapy with IL , IFN ?, or anti PD , anti PD L, anti PD L, anti CD, or anti cytotoxic T lymphocyte associated antigen  (anti CTLA ) antibody (including ipilimumab), or any other antibody or drug specifically targeting T cell co stimulation or immune checkpoint pathways
Prior therapy with experimental anti-tumor vaccines; any T cell co-stimulation or checkpoint pathways, such as anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or anti-CTLA- antibody, including Ipilimumab; or other medicines specifically targeting T cell is also prohibited
Prior therapy with an anti PD , anti PD L, anti PD L, anti CD, or anti cytotoxic T lymphocyte associated antigen  (CTLA ) antibody (including ipilimumab, tremelimumab or any other antibody or drug specifically targeting T cell co stimulation or immune checkpoint pathways).
Prior therapy with an anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or anti-cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including pembrolizumab, ipilimumab, and any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Subject has been previously treated with an anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or anti-CTLA- antibody or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways;
Received prior immune checkpoint inhibitors (e.g., anti-CTLA-, anti-PD-, anti PDL-) and any other antibody or drug specifically targeting T-cell costimulation or an IDO inhibitor
Prior systemic treatment with and anti-PD, anti-PD-L, anti-PD-L, anti-CTLA- antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways
Prior therapy with an anti-PD-, anti-PD-L, anti-PDL-, or anti-CTLA- antibody (or any other antibody targeting T cell co-stimulation pathways)
Patients who have had prior therapy with nivolumab or with an anti-programmed cell death (PD)-, anti-PD-ligand (L), anti-PD-L, anti-cytotoxic T-lymphocyte-antigen (CTLA)- antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune check point pathways
Prior therapy with an anti-programmed cell death (PD)-, anti-PD-L, anti-PD-L, anti-tumor necrosis factor CD, or anti-cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways), or took part in another pembrolizumab trial
Prior immune therapy for NSCLC excluded. Patients should be excluded if they have had prior treatment with an anti-PD-, anti-PD-L, anti PD-L, anti-CTLA- antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways.
Participants may not have received any prior treatment with an anti-PD-, anti PD-L, anti-PD-L, anti-CTLA- antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
Prior treatment with an anti-PD-, anti-PD-L, anti-PD-L, anti-CTLA- antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
Has received prior therapy with an anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or anti-cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Prior immunotherapy with IL-, IFN-?, or anti PD , anti PD L, anti PD L, anti CD, or anti cytotoxic T lymphocyte associated antigen  (CTLA ) antibody (including ipilimumab), or any other antibody or drug specifically targeting T cell co stimulation or immune checkpoint pathways
Has received prior therapy with an anti-PD-, anti-PD-L, anti-PD-L, anti-cluster of differentiation (CD), or anti-cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Has received prior therapy with an anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or anti-cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Prior treatment with an anti-PD-,anti-PD-L,anti-PD-L,anti-cytotoxic T-lymphocyte-associated protein  (CTLA-) antibody, anti-CD or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways Exclusion laboratory criteria:
Has received prior therapy with an anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or anti-cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).
Received prior therapy with an anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or anti-Cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).
Prior treatment with an anti-PD-, anti-PD-L, anti-PD-L, anti-cytotoxic T-lymphocyte antigen  (CTLA-) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
Has received prior therapy with an anti-programmed cell death (PD)-, anti-PD ligand (PD-L), anti-PD-L, anti-cluster of differentiation (CD) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Has received prior therapy with an anti-programmed cell death (PD)-, anti-PD-L, anti-PD-L, anti-cluster of differentiation (CD), or anti-cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Has received prior therapy with an anti-PD-, anti-PD-L, anti-PD-L, anti-cluster of differentiation (CD), or anti-cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Patients should be excluded if they have had prior treatment with an anti-PD-, anti-PD-L, anti-programmed cell death ligand  (PD-L), anti-cytotoxic T-lymphocyte-associated protein  (CTLA-) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
Has received prior therapy with an anti-programmed cell death (PD)-, anti-PD-ligand (L), anti-PD-L, anti-cluster of differentiation (CD), or anti-cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways); previous treatment with sipuleucel-T is permitted
Has received prior therapy with an anti-PD-, anti-PD-L, anti-PD-L, anti-cluster of differentiation (CD), or anti-cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or other antibody or drug specifically targeting T-cell co-stimulation)
Has received prior therapy with an anti-programmed cell death protein  (PD-), anti-PD-L, anti-PD-L, anti-cluster of differentiation  (CD), or anti-cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Prior treatment with an anti-programmed death (PD)-, anti-PD-L, anti-PD-L, anti-CD, or anti-cytotoxic T-lymphocyte antigen  (CTLA-) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Has previously participated in any other pembrolizumab (MK-) trial, or received prior therapy with an anti-PD-, anti-PD-L, and anti-PD-L (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Prior Therapies:\r\n* Treatment with a monoclonal antibody within  weeks prior to study day  or has not recovered (i.e., >= grade  at baseline) from adverse events due to agents administered >  weeks earlier\r\n* Prior chemotherapy, targeted small molecule therapy, within  weeks prior to study day  or has not recovered (i.e., >= grade  at baseline) from adverse events due to a previously administered agent (excluding grade  neuropathy)\r\n* Prior therapy with an anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or anti-cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Prior immunotherapy with IL-, IFN-?, or an anti-PD-, anti-PD-L, anti-PD-L, anti-CD, OX , GITR, LAG , IDO, TDO,TIM , CTLA- antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways. Prior treatment with Sipuleucel-T for patients with mCRPC is allowed.
Prior therapy with an anti-PD-, anti-PD-L, anti-PD-L, anti-CD, anti-CTLA- antibody or any other antibody or drug specifically targeting T cell co-stimulation or immune checkpoint pathways
Has received prior therapy with an anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or anti-cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways) for the immunotherapy-naive cohort only
Patients should be excluded if they have had prior systemic treatment with an anti-PD-, anti-PD-L, anti-PD-L, anti-CTLA- antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways
Prior treatment with immune checkpoint inhibitors (eg, anti-CTLA-, anti-PD-, anti-PD-L, and any other antibody or drug specifically targeting T-cell co-stimulation) or an IDO inhibitor.
Prior immunotherapy with IL-, IFN-?, or an anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or CTLA  antibody (including ipilimumab), or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
Prior therapy for melanoma with the following exceptions which are allowed: ) surgery for the melanoma lesion(s), ) adjuvant RT after neurosurgical resection for CNS lesions, and ) prior adjuvant IFN (see qualifier below). Specifically, patients who received prior therapy with anti-PD-, anti PD L, anti-PD-L, anti-CD, or anti-CTLA- antibody (including ipilimumab or any other antibody or drug specifically targeting T cell costimulation or checkpoint pathways) are not eligible.  Prior treatment with adjuvant IFN is allowed if completed ?  months prior to treatment.
Pre-treatment with anti-CTLA antibodies in combination with any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathway.
Has received prior therapy with an anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or anti-cytotoxic\r\nT-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Has received prior therapy with an anti-programmed cell death protein  (PD-), anti-PD-L, anti-PD-L, anti-CD, or anti-cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Prior therapy with anti-PD-, anti-PD-L, anti-PD-L, anti-CD, or anti-CTLA- antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Prior therapy with an anti-PD-, anti-PD-L, anti-PD-L, or anti-cytotoxic T-lymphocyte-associated protein- (CTLA-) antibody (or any other antibody targeting T-cell co-stimulation pathways).
Prior treatment with any anti-Programmed Death (PD)-, or PD-L or PD-L agent; or with azacitidine (any formulation) or any other hypomethylating agent; or with anti-cytoplasmic (CD) , or anti-cytotoxic T-Lymphocyte Associated Protein (CTLA)- antibody (including ipilimumab) or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.
Patients should be excluded if they have had prior treatment with an anti-PD-, anti-PD-L, anti-PD-L, anti-CTLA- antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
Has received prior therapy with an anti-PD-, anti-PD-L, anti-PD-L, anti-cluster of differentiation (CD), or anti-cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Has received prior therapy with an anti-programmed cell death- (anti-PD-), anti-PD-ligand  (anti-PD-L), anti-PD-L, anti-CD, or cytotoxic T-lymphocyte-associated protein  (CTLA-) antibody (including ipilimumab) or OX- (Tumor necrosis factor receptor superfamily, member  [TNFRSF]), or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.
Has received prior therapy with an anti-PD-, anti-PD-L, anti-PD-L, anti-cluster of differentiation (CD), or anti-cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
